ArticleInternational journal of molecular sciences2023
Prognostic Impact of Dihydropyrimidine Dehydrogenase Germline Variants in Unresectable Non-Small Cell Lung Cancer Patients Treated with Platin-Based Chemotherapy.
Javier Guijarro-Eguinoa, Sara Arjona-Hernandez, Stefan Stewart, Olga Pernia, Pedro Arias, Itsaso Losantos-García, Tania Rubio, Miranda Burdiel, Carlos Rodriguez-Antolin, Patricia Cruz-Castellanos and 6 more
Open access · goldAbstract read
In one paragraphArticle in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 63% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
16 authors at 3 institutions in 1 country.
Javier Guijarro-EguinoaClinical Pharmacology Department, La Paz University Hospital, 28046 Madrid, Spain.
Sara Arjona-HernandezLaboratory Medicine Department, Puerta Del Mar University Hospital, 11009 Cadiz, Spain.
Olga PerniaCancer Epigenetics Laboratory, Genetics Department, La Paz University Hospital, 28046 Madrid, Spain.
Pedro AriasPharmacogenetics Laboratory, Genetics Department, La Paz University Hospital, 28046 Madrid, Spain.
Itsaso Losantos-GarcíaBiostatistics Department, Hospital La Paz Institute for Health Research-IdiPAZ, 28029 Madrid, Spain.ORCID 0000-0001-5338-7438 Tania RubioCancer Epigenetics Laboratory, Genetics Department, La Paz University Hospital, 28046 Madrid, Spain.
Miranda BurdielCancer Epigenetics Laboratory, Genetics Department, La Paz University Hospital, 28046 Madrid, Spain.
Carlos Rodriguez-AntolinCancer Epigenetics Laboratory, Genetics Department, La Paz University Hospital, 28046 Madrid, Spain.ORCID 0000-0001-6682-0771 Patricia Cruz-CastellanosExperimental Therapies and Novel Biomarkers in Cancer, Hospital La Paz Institute for Health Research-IdiPAZ, 28029 Madrid, Spain.
Alberto M BorobiaClinical Pharmacology Department, La Paz University Hospital, 28046 Madrid, Spain.
Sonia Rodriguez-NovoaGenetics of Metabolic Diseases Laboratory, Genetics Department, La Paz University Hospital, 28046 Madrid, Spain.ORCID 0000-0003-4225-3631 Javier de Castro-CarpeñoExperimental Therapies and Novel Biomarkers in Cancer, Hospital La Paz Institute for Health Research-IdiPAZ, 28029 Madrid, Spain.ORCID 0000-0002-3622-6306 Inmaculada Ibanez de CaceresCancer Epigenetics Laboratory, Genetics Department, La Paz University Hospital, 28046 Madrid, Spain.ORCID 0000-0001-9805-8486 Rocio Rosas-AlonsoExperimental Therapies and Novel Biomarkers in Cancer, Hospital La Paz Institute for Health Research-IdiPAZ, 28029 Madrid, Spain.ORCID 0000-0002-3331-2161 Hospital Universitario La Paz · ESHospital La Paz Institute for Health Research · ESHospital Universitario Puerta del Mar · ES
Funding
Instituto de Salud Carlos III CA22/00002Instituto de Salud Carlos III FI19/00061Instituto de Salud Carlos III JR21/00003Instituto de Salud Carlos III PI18/00050Instituto de Salud Carlos III PI21/00145Instituto de Salud Carlos III PI22/00128
6 · The paper itselfAbstract
Platin-based chemotherapy is the standard treatment for patients with non-small cell lung cancer (NSCLC). However, resistance to this therapy is a major obstacle in successful treatment. In this study, we aimed to investigate the impact of several pharmacogenetic variants in patients with unresectable NSCLC treated with platin-based chemotherapy. Our results showed that
Indexed as
Carcinoma, Non-Small-Cell LungLung NeoplasmsDihydrouracil Dehydrogenase (NADP)FluorouracilGerm CellsHumansPrognosisDihydrouracil Dehydrogenase (NADP)FluorouracilcarboplatincisplatinDPYDnon-small cell lung cancerpharmacogeneticsplatinum resistance
Identifiers
PMID37372990
PMCPMC10298094
OpenAlexW4379797658
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390